A clinical trial of CCNU (1‐(2 chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea) (NSC 79037) in advanced ovarian carcinoma

Truman M. Sasaki, Donald B. McConnell, H. Stephens Moseley, G. Craig Merhoff, William S. Fletcher

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

CCNU is a useful drug in treating advanced ovarian carcinoma. Of patients with advanced ovarian carcinoma 37% responded favorably to CCNU. Thrombocytopenia was the primary toxic reaction. Clinical trials are in progress to compare the relative effectiveness, the degree of cross‐resistance, and the difference in toxicity between CCNU and alkylating agents.

Original languageEnglish (US)
Pages (from-to)347-350
Number of pages4
JournalJournal of surgical oncology
Volume7
Issue number5
DOIs
StatePublished - 1975

Keywords

  • CCNU
  • ovarian carcinoma

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'A clinical trial of CCNU (1‐(2 chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea) (NSC 79037) in advanced ovarian carcinoma'. Together they form a unique fingerprint.

Cite this